DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
TOSEDOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Aminopeptidase inhibitor
TOSEDOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
KZK563J2UW
Molecule Type:
Small molecule
Molecular Formula:
C21H30N2O6
Molecular Weight:
406.48
AlogP:
1.86
PSA:
124.96
HBD:
4.0
HBA:
#RotB:
9.0
Source:
PF-00446687
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Sexual Dysfunction, Physiological
Melanocortin receptor 4 agonist
PF-00446687
×
Maximum Phase:
2
First Approval:
None
UNII:
63P236Z73I
Molecule Type:
Small molecule
Molecular Formula:
C28H36F2N2O2
Molecular Weight:
470.6
AlogP:
4.78
PSA:
43.78
HBD:
1.0
HBA:
#RotB:
3.0
Source:
ITRIGLUMIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cholecystokinin B receptor antagonist
ITRIGLUMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
879A12466H
Molecule Type:
Small molecule
Molecular Formula:
C33H38N2O4
Molecular Weight:
526.68
AlogP:
6.84
PSA:
86.71
HBD:
2.0
HBA:
#RotB:
7.0
Source:
M5A 90Y
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
M5A 90Y
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DULIGOTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
DULIGOTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
8PMF8YQX2T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DACETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse
Tumor necrosis factor receptor superfamily member 5 inhibitor
DACETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
UT59FF4T5X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
J591
2
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
J591
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEDORADRINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BEDORADRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
4EAR229231
Molecule Type:
Small molecule
Molecular Formula:
C24H32N2O5
Molecular Weight:
428.53
AlogP:
1.57
PSA:
102.26
HBD:
4.0
HBA:
#RotB:
9.0
Source:
CBX129801
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CBX129801
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAFOTIBANT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Bradykinin B1 receptor antagonist
SAFOTIBANT
×
Maximum Phase:
2
First Approval:
None
UNII:
02HU8HWP7U
Molecule Type:
Small molecule
Molecular Formula:
C25H34N4O5S
Molecular Weight:
502.64
AlogP:
1.96
PSA:
100.54
HBD:
1.0
HBA:
#RotB:
11.0
Source:
CI-1040
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Pancreatic Neoplasms
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
CI-1040
×
Maximum Phase:
2
First Approval:
None
UNII:
R3K9Y00J04
Molecule Type:
Small molecule
Molecular Formula:
C17H14ClF2IN2O2
Molecular Weight:
478.66
AlogP:
5.04
PSA:
50.36
HBD:
2.0
HBA:
#RotB:
6.0
Source:
TESOFENSINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Diabetes Mellitus, Type 2; Obesity; Parkinson Disease; Prader-Willi Syndrome
Monoamine transporter inhibitor
TESOFENSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
BLH9UKX9V1
Molecule Type:
Small molecule
Molecular Formula:
C17H23Cl2NO
Molecular Weight:
328.28
AlogP:
4.6
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ONTUXIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Melanoma; Sarcoma
Endosialin inhibitor
ONTUXIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0M2XT000YC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLENDALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Antiphospholipid Syndrome; Graft vs Host Disease
Complement C5 inhibitor
OLENDALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4971UQC7F3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGCRISANTASPASE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PEGCRISANTASPASE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6927005
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
RO6927005
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RELATLIMAB
2
Antibody
Investigational
Unknown
Unknown
Glioblastoma; Gliosarcoma; Hematologic Neoplasms; Multiple Myeloma; Colorectal Neoplasms
Lymphocyte activation gene 3 protein inhibitor
RELATLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AF75XOF6W3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OXIRACETAM
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Unknown
OXIRACETAM
×
Maximum Phase:
2
First Approval:
None
UNII:
P7U817352G
Molecule Type:
Small molecule
Molecular Formula:
C6H10N2O3
Molecular Weight:
158.16
AlogP:
-1.94
PSA:
83.63
HBD:
2.0
HBA:
#RotB:
2.0
Source:
GALLOPAMIL
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Cardiovascular Diseases
Unknown
GALLOPAMIL
×
Maximum Phase:
2
First Approval:
None
UNII:
39WPC8JHR8
Molecule Type:
Small molecule
Molecular Formula:
C28H40N2O5
Molecular Weight:
484.64
AlogP:
5.1
PSA:
73.18
HBD:
0.0
HBA:
#RotB:
14.0
Source:
AMLISIMOD
2
Protein
Investigational
Unknown
Unknown
Dry Eye Syndromes
Unknown
AMLISIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UPAMOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Severe Acute Respiratory Syndrome
Unknown
UPAMOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
S5M7KW6U17
Molecule Type:
Small molecule
Molecular Formula:
C32H47N5O6S
Molecular Weight:
629.82
AlogP:
4.34
PSA:
154.63
HBD:
3.0
HBA:
#RotB:
11.0
Source:
KELIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 negative modulator
KELIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIMUFILAM
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Unknown
SIMUFILAM
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C15H21N3O
Molecular Weight:
259.35
AlogP:
1.04
PSA:
35.58
HBD:
1.0
HBA:
#RotB:
2.0
Source:
LY2245461
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Estrogen receptor modulator
LY2245461
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-906024
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Breast Neoplasms; Carcinoma, Adenoid Cystic
Unknown
BMS-906024
×
Maximum Phase:
2
First Approval:
None
UNII:
DRL23N424R
Molecule Type:
Small molecule
Molecular Formula:
C26H26F6N4O3
Molecular Weight:
556.51
AlogP:
4.35
PSA:
104.86
HBD:
2.0
HBA:
#RotB:
9.0
Source:
GENISTEIN
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Cystic Fibrosis; Neoplasms; Rectal Neoplasms; Breast Neoplasms; Coronary Disease; Metabolic Syndrome; Osteoporosis; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pulmonary Fibrosis; Urinary Bladder Neoplasms
Unknown
GENISTEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DH2M523P0H
Molecule Type:
Small molecule
Molecular Formula:
C15H10O5
Molecular Weight:
270.24
AlogP:
2.58
PSA:
90.9
HBD:
3.0
HBA:
#RotB:
1.0
Source:
LABETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms
Carcinoembryonic antigen-related cell adhesion molecule 5 other
LABETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
EFE6X5M3UY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAVELERTINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
MAVELERTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
YXX2180047
Molecule Type:
Small molecule
Molecular Formula:
C18H22FN9O2
Molecular Weight:
415.43
AlogP:
0.68
PSA:
115.02
HBD:
2.0
HBA:
#RotB:
6.0
Source:
LERIDISTIM
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
LERIDISTIM
×
Maximum Phase:
2
First Approval:
None
UNII:
WYY7RA43DK
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELUBRIXIN
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Cystic Fibrosis
Interleukin-8 receptor B antagonist
ELUBRIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
MW2AIJ8USP
Molecule Type:
Small molecule
Molecular Formula:
C17H17Cl2FN4O4S
Molecular Weight:
463.32
AlogP:
3.08
PSA:
110.77
HBD:
4.0
HBA:
#RotB:
4.0
Source:
RELCOVAPTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Oxytocin receptor antagonist
RELCOVAPTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
C1GL8G6G0O
Molecule Type:
Small molecule
Molecular Formula:
C28H27Cl2N3O7S
Molecular Weight:
620.51
AlogP:
3.3
PSA:
139.47
HBD:
2.0
HBA:
#RotB:
7.0
Source:
VANUTIDE CRIDIFICAR
2
Protein
Investigational
Unknown
Unknown
Alzheimer Disease
Beta amyloid A4 protein vaccine antigen
VANUTIDE CRIDIFICAR
×
Maximum Phase:
2
First Approval:
None
UNII:
9HRI13ZIDX
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CP-778875
2
Small molecule
Investigational
Unknown
Unknown
Lipid Metabolism Disorders
Peroxisome proliferator-activated receptor alpha agonist
CP-778875
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-232798
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
C-C chemokine receptor type 5 inhibitor
PF-232798
×
Maximum Phase:
2
First Approval:
None
UNII:
63P7W7886U
Molecule Type:
Small molecule
Molecular Formula:
C29H40FN5O2
Molecular Weight:
509.67
AlogP:
4.31
PSA:
70.47
HBD:
1.0
HBA:
#RotB:
7.0
Source:
RIMTUZALCAP
2
Small molecule
Investigational
Unknown
Unknown
Essential Tremor
Unknown
RIMTUZALCAP
×
Maximum Phase:
2
First Approval:
None
UNII:
USO2D5J77R
Molecule Type:
Small molecule
Molecular Formula:
C18H24F2N6O
Molecular Weight:
378.43
AlogP:
2.8
PSA:
68.1
HBD:
1.0
HBA:
#RotB:
4.0
Source:
1
2
…
169
170
171
172
173
174
175
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA